Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Results from the Phase III CheckMate 77T study were published today in the New England Journal...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ABSTRACT: LBA-2
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS)...
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University...
ABSTRACT: 77
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms...
ABSTRACTS: 57, 58
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated...
ABSTRACT: GA03-03
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease-free survival (iDFS...
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development...
ABSTRACTS: RF01-04 and RF01-07
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical...
ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983
SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights...
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced...
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson...
Incorporating navy beans into the diet of colorectal cancer (CRC) survivors has the potential to positively impact both gut and host health...
First author Cullen Taniguchi, M.D., Ph.D., passed away suddenly before the final publication of this study. A talented physician-scientist...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its inaugural scientific symposium on Nov. 10 at...
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration...
ABSTRACTS: 1534, 777, 1328, 1526, 1330, 545
The University of Texas MD Anderson Cancer Center’s Research...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival...
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses...
ABSTRACT: LBA41
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (...
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance...
ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO
The University of Texas MD Anderson Cancer Center’s Research Highlights...
The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring...
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine and core member of the James P. Allison...
The University of Texas MD Anderson Cancer Center today announced the launch of Texas Health Equity Alliance for Breast Cancer (THEAL), a...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston today announced Alejandro Aballay...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center today broke ground on a 600,000-square-foot facility intended to anchor the institution’...
Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective...
Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung...
By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid...
The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer...
The University of Texas MD Anderson Cancer Center was awarded four grants totaling nearly $4.9 million from the Cancer Prevention and Research...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative...
The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, M.D., an internationally recognized physician-scientist...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen...
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts in Mozambique and Brazil, including...
The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe...
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the...
A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying...
A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of Medicine...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting...
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner...
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing...
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ABSTRACT: LBA107
CHICAGO – Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival...
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated...
ABSTRACT: LBA3000
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging...
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2...
A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper...
ABSTRACTS: 398868, 425082, 6546, 3501, 6008, 9502, 9011, 9008
CHICAGO ― The University of Texas MD Anderson Cancer Center’s Research...
ABSTRACT: 7003
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative...
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the appointment of its first members,...
MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the prestigious National Academy of...
The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover...
The American Society of Clinical Oncology (ASCO) will present the 2023 David A. Karnofsky Memorial Award to Hagop Kantarjian, M.D...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ABSTRACT: 5788
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest single-cell atlas...
ABSTRACTS: CT016, CT018
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings...
ABSTRACT: 3431
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations...
ABSTRACT: CT011
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response...
ABSTRACT: CT006
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the 2023 class of Fellows of the American Association...
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Florencia McAllister receives TAMEST Mary Beth Maddox Award for pancreatic tumor microbiome research
Florencia McAllister, M.D., associate professor of Clinical Cancer Prevention, Gastrointestinal Medical Oncology and Immunology at The University...
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical...
The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research...
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company...
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells...
Risk model-based lung cancer screening strategies, which select individuals based on personal risk, are more cost effective than current recommendations...
A study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Cell Biology, details a previously...
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts through a new agreement with...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
Three researchers at The University of Texas MD Anderson Cancer Center have been named fellows of the American Association for the Advancement...
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when...
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson...
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has received...
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved...